雷贝拉唑联合莫沙必利治疗反流性食管炎的临床疗效及安全性分析

陶金华

陶金华. 雷贝拉唑联合莫沙必利治疗反流性食管炎的临床疗效及安全性分析[J]. 实用临床医药杂志, 2012, (17): 94-96.
引用本文: 陶金华. 雷贝拉唑联合莫沙必利治疗反流性食管炎的临床疗效及安全性分析[J]. 实用临床医药杂志, 2012, (17): 94-96.
TAO Jin-hua. Clinical efficacy and safety of rabeprazole combined with mosapride in the treatment of reflux esophagitis[J]. Journal of Clinical Medicine in Practice, 2012, (17): 94-96.
Citation: TAO Jin-hua. Clinical efficacy and safety of rabeprazole combined with mosapride in the treatment of reflux esophagitis[J]. Journal of Clinical Medicine in Practice, 2012, (17): 94-96.

雷贝拉唑联合莫沙必利治疗反流性食管炎的临床疗效及安全性分析

基金项目: 中国高校医学期刊临床专项资金
详细信息
  • 中图分类号: R571

Clinical efficacy and safety of rabeprazole combined with mosapride in the treatment of reflux esophagitis

  • 摘要: 目的 探讨雷贝拉唑联合莫沙必利治疗反流性食管炎(RE)的临床疗效及安全性.方法 将90例RE患者随机分为2组,观察组予雷贝拉唑联合莫沙必利,对照组给予奥美拉唑联合莫沙必利.比较2组症状评分的变化、临床症状和胃镜下征象的总体疗效,以及不良反应.结果 治疗4周、8周时症状评分均较治疗前显著下降;治疗4周时,观察组各症状评分下降程度大于对照组,治疗8周时,观察组胸骨后烧灼痛的症状评分显著低于对照组.观察组临床症状治愈率显著高于对照组,观察组胃镜下征象的治愈率及总有效率均高于对照组,2组不良反应发生率无显著差异,且均可耐受.结论 雷贝拉唑联合莫沙必利对RE的临床症状及胃镜下征象的改善作用较好,且安全性高,可作为反流性食管炎的首选治疗方案.
  • Nagahara A, Hojo M, Asaoka D. Clinical feature of asymptomatic reflux esophagitis in patients who underwent upper gastrointestinal endoscopy [J]. Journal of Gastroenterology and Hepatology, 2012, (Suppl 3):53.
    Imamoto H, Hashimoto N, Shiozaki H. Effect of PPI (rabeprazole) on reflux esophagitis after total gastrectomy [J]. Hepato-Gastroenterology, 2011, (110-111):1574.
    Frootan M, Choobtashani S, Azargashb E. Non-erosive reflux disease compared with erosive esophagitis with regards to acid reflux and symptom patterns [J]. Turkish Journal of Gastroenterology, 2011(5):464.
    Illueca M, Wernersson B, Henderson C. Maintenance treatment with proton pump inhibitors for reflux esophagitis in pediatric patients:a systematic literature analysis [J]. Journal of Pediatric Gastroenterology and Nutrition, 2010(6):733.
    刘 洋, 黄玉凯. 莫沙必利与奥美拉唑联合治疗反流性食管炎45例疗效观察 [J]. 实用临床医药杂志, 2008(7):49.doi: 10.3969/j.issn.1672-2353.2008.07.020.
    Kinoshita Y, Hongo M, Japan TWICE Study Group. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI:the Japan-based TWICE study [J]. American Journal of Gastroenterology, 2012(4):522.
    Filik L. Long-term maintenance therapy with rabeprazole for reflux esophagitis [J]. Internal Medicine, 2011, (11):1267.
    Keller G A, Czerniuk P, Bertuola R. Relative bioavailability of a 5 mg mosapride/10 mg rabeprazole fixed dose combination tablet versus separate single tablets in healthy volunteers:a single-dose randomized open-label crossover study [J]. Current Medical Research and Opinion, 2011, (11):2203.
计量
  • 文章访问数: 
  • HTML全文浏览量: 
  • PDF下载量: 
  • 被引次数: 0
出版历程
  • 发布日期:  2013-01-15

目录

    /

    返回文章
    返回